Key points from article :
Swiss startup IsoSpec Analytics has received funding to develop a technology that quickly identifies unknown molecules within biological samples.
This technology has potential applications in developing new medications and finding biomarkers that can signal the presence of diseases.
Founded by researchers at the Swiss Federal Institute of Technology (EPFL), IsoSpec's technology goes beyond traditional mass analysis by adding infrared spectroscopy for more accurate and faster results.
The goal of IsoSpec is to help analyze the vast number of unknown molecules in human biology, such as in blood samples, which could hold keys to new treatments.
This new funding will enable IsoSpec to automate its platform and use machine learning for better data analysis.
